# INTerpath-005 (NCT06305767)

> A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06305767
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Bladder Cancer
- Interventions: Pembrolizumab; Intismeran autogene; Placebo; Enfortumab Vedotin; Surgery (RC plus PLND)
- Enrollment: 230
- Primary outcome: Adjuvant Cohort: Disease Free Survival (DFS)
- Primary outcome: Perioperative Cohort: Number of Participants Who Experience an Adverse Event (AE)
- Primary outcome: Perioperative Cohort: Number of Participants Who Discontinue Study Treatment Due to AE

## Indexed commentary on INTerpath-005 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=interpath-005-nct06305767